Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 May 21;17(5):790. doi: 10.3390/ijms17050790

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 by the authors; licensee MDPI, Basel, Switzerland.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

PD-L1 staining in epithelial tumors: (A) incomplete immunoreactivity of membrane in breast cancer sample (40×); (B) complete immunoreactivity of membrane in breast cancer sample (40×); (C) incomplete immunoreactivity of membrane in ovarian cancer sample without cytoplasmic staining (40×); (D) incomplete immunoreactivity of membrane in thyroid cancer sample with mild cytoplasmic staining (40×); (E) incomplete immunoreactivity of membrane in colon cancer sample (40×); (F) complete immunoreactivity of membrane in colon cancer sample (40×); (G) incomplete immunoreactivity of membrane with mild cytoplasmic staining in lung cancer sample (40×); (H) complete immunoreactivity of membrane with mild cytoplasmic staining in lung cancer sample (40×); (I) incomplete immunoreactivity of membrane without cytoplasmic staining in kidney cancer sample (40×); (L) complete immunoreactivity of membrane with cytoplasmic staining in kidney cancer sample (40×); (M) incomplete immunoreactivity of membrane in melanoma sample (40×); and (N) complete immunoreactivity of membrane in melanoma sample (40×).

PD-L1 staining in epithelial tumors: (A) incomplete immunoreactivity of membrane in breast cancer sample (40×); (B) complete immunoreactivity of membrane in breast cancer sample (40×); (C) incomplete immunoreactivity of membrane in ovarian cancer sample without cytoplasmic staining (40×); (D) incomplete immunoreactivity of membrane in thyroid cancer sample with mild cytoplasmic staining (40×); (E) incomplete immunoreactivity of membrane in colon cancer sample (40×); (F) complete immunoreactivity of membrane in colon cancer sample (40×); (G) incomplete immunoreactivity of membrane with mild cytoplasmic staining in lung cancer sample (40×); (H) complete immunoreactivity of membrane with mild cytoplasmic staining in lung cancer sample (40×); (I) incomplete immunoreactivity of membrane without cytoplasmic staining in kidney cancer sample (40×); (L) complete immunoreactivity of membrane with cytoplasmic staining in kidney cancer sample (40×); (M) incomplete immunoreactivity of membrane in melanoma sample (40×); and (N) complete immunoreactivity of membrane in melanoma sample (40×).